LifeMD Earnings Call Transcripts
Fiscal Year 2026
-
Q2 revenue was $47.3M, with gross margin expanding to 89% and recurring bill revenue at 84%. Strategic shifts to branded therapies, longer memberships, and diversified acquisition channels led to a revised 2026 outlook, but profitability is expected to improve in H2.
-
A leading virtual care provider is expanding from men's health into high-growth areas like GLP-1 weight management, women's health, psychiatry, and cardiology, leveraging proprietary AI and integrated pharmacy infrastructure. Strong revenue growth, high margins, and a shift toward insurance coverage position the business for continued expansion and profitability.
-
Q1 2026 saw revenue of $50.2M, record subscriber growth, and strong momentum in weight management and women's health. Gross margin expanded to 88%, and full-year guidance was reaffirmed, with profitability expected in the second half as acquisition costs decline.
Fiscal Year 2025
-
Delivered record Q4 and full-year results with 25% revenue growth, strong subscriber gains, and margin expansion. Aggressive investments in patient acquisition and AI-driven care are expected to drive 2026 revenue to $220–$230 million, with pharmacy and specialty care as key growth drivers.
-
Q3 2025 saw 13% revenue growth and 30% higher adjusted EBITDA, with strong telehealth and RexMD performance. Insurance enablement and new oral GLP-1 therapies are set to drive growth in 2026, while the company maintains a robust balance sheet and focuses on core virtual care.
-
Q2 2025 saw 23% revenue growth and a 560% jump in telehealth adjusted EBITDA, despite RexMD headwinds and higher weight management refunds. Guidance was revised lower, but new launches in behavioral and women's health, plus insurance expansion, position the business for long-term growth.
-
Q1 2025 saw 49% revenue growth and first positive GAAP net income, driven by strong telehealth and new service lines. Guidance for 2025 was raised, with continued expansion in Medicare, GLP-1 partnerships, and new health verticals expected to fuel growth.
Fiscal Year 2024
-
Record 2024 results with 43% Q4 revenue growth and strong telehealth/WorkSimpli performance. 2025 guidance projects up to $275M revenue and $32M adjusted EBITDA, with new launches in behavioral health, pharmacy, and insurance expected to drive growth.
-
Q3 saw 38% revenue growth and record gross margins, with telehealth revenue up 65% year-over-year and Adjusted EBITDA exceeding guidance. The company launched a national pharmacy, expanded payer contracts, and enhanced its weight management and men's health offerings.
-
Core telehealth business delivered 67% year-over-year revenue growth and achieved profitability ahead of schedule, driven by strong weight management performance and improved retention. WorkSimpli faced challenges but is expected to recover by year-end. Full-year revenue guidance was reiterated, with telehealth guidance raised and consolidated EBITDA guidance lowered due to WorkSimpli.